New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: Glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2)

Diabetes, Obesity and Metabolism

Volumn 18, Issue 4, 2016, Pages 366-374

  Terauchi, Y ^a   Koyama, M ^b   Cheng, X ^c   Takahashi, Y ^b   Riddle, M C ^d   Bolli, G B ^e   Hirose, T ^f  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Sanofi KK   (Japan)

^c Sanofi Pasteur   (China)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF PERUGIA   (Italy)

^f TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Basal insulin; Glycaemic control; Insulin analogues; Phase III study; Randomized trial; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; DELAYED RELEASE FORMULATION; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ALLERGIC REACTION; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STOMACH ULCER; TIBIA FRACTURE; UNSPECIFIED SIDE EFFECT; WEIGHT CHANGE; ADMINISTRATION AND DOSAGE; ADVERSE EFFECTS; AGED; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; HYPERGLYCEMIA; JAPAN; MIDDLE AGED; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; RISK; THERAPEUTIC USE;

ADMINISTRATION, ORAL; AGED; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN DETEMIR; INSULIN GLARGINE; JAPAN; MALE; MIDDLE AGED; RISK;

EID: 84960080223     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12618     Document Type: Article

References (24)

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2015. 7. Approaches to glycemic treatment. Diabetes Care 2015; 38: S41-S48.
2. Polonsky WH, Fisher L, Guzman S, Villa-Caballero L, Edelman SV. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care 2005; 28: 2543-2545.
3. Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med 2012; 29: 682-689.
4. Mukai N, Doi Y, Ninomiya T et al. Trends in the prevalence of type 2 diabetes and prediabetes in community-dwelling Japanese subjects: the Hisayama Study. J Diabetes Investig 2014; 5: 162-169.
5. Neville SE, Boye KS, Montgomery WS, Iwamoto K, Okamura M, Hayes RP. Diabetes in Japan: a review of disease burden and approaches to treatment. Diabetes Metab Res Rev 2009; 25: 705-716.
6. Kishida K, Funahashi T, Shimomura I. Clinical importance of assessment of type 2 diabetes mellitus with visceral obesity. A Japanese perspective. Curr Diabetes Rev 2012; 8: 84-91.
7. Owens DR. Insulin preparations with prolonged effect. Diabetes Technol Ther 2011; 13(Suppl. 1): S5-S14.
8. -1. Diabetes Care 2015; 38: 637-643.
9. Shiramoto M, Eto T, Irie S et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015; 17: 254-260.
10. Riddle MC, Bolli GB, Zieman M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal and mealtime insulin: glucose and hypoglycemia in a 6-month randomized controlled trial (EDITION I). Diabetes Care 2014; 37: 2755-2762.
11. Yki-Järvinen H, Bergenstal RM, Zieman M et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014; 37: 3235-3243.
12. Bolli GB, Riddle MC, Bergenstal RM et al. New insulin glargine 300 U/mL compared with glargine 100 U/mL in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015; 17: 386-394.
13. Home PD, Bergenstal RM, Bolli GB et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with Type 1 diabetes: a randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care 2015; 38: 2217-2225.
14. Matsuhisa M, Koyama M, Cheng X, Shimizu S, Hirose T. New insulin glargine 300 U/mL: glycemic control and hypoglycaemia in Japanese people with type 1 diabetes mellitus (EDITION JP 1). Diabetologia 2014; 57: S400.
15. ICH. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice E6 (R1), 1996.
16. World Medical Association. Declaration of Helsinki. Ethical principles for medical research involving human subjects, 2013.
17. ADA Workgroup on Hypoglycemia. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245-1249.
18. Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig 2013; 4: 605-612.
19. Suzuki D, Toyoda M, Kondo M et al. Efficacy of long-acting insulin analog insulin glargine at high dosage for basal-bolus insulin therapy in patients with type 2 diabetes. Tokai J Exp Clin Med 2012; 37: 35-40.
20. Oishi M, Abe N, Yokoyama H et al. Observational 6-month open-label study of Japanese type 2 diabetes patients switching from NPH insulin to insulin detemir in basal-bolus regimen: 23rd article of the Japan Diabetes Clinical Data Management Study Group (JDDM23). J Int Med Res 2012; 40: 787-797.
21. Saisho Y. Obesity, type 2 diabetes and beta cell failure: an Asian perspective. J Mol Genet Med 2014; S1: 008.
22. Arai K, Matoba K, Hirao K et al. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15, 652 patients. Endocr J 2010; 57: 499-507.
23. Karl DM, Gill J, Zhou R, Riddle MC. Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 622-628.
24. Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367: 319-328.